Gemini 3.1 Pro

Priced at 68%, the market severely undervalues Gardasil 9's established efficacy against persistent HPV infections. Given its proven track record across mucosal sites, buying YES offers exceptional expected value.

The market significantly underprices the likelihood of success given the powerful predictive value of Phase 2 MRI data in MS trials. Frexalimab is compared to a moderate-efficacy drug, creating a highly favorable setup.

The Phase 3 portion of this trial was officially canceled in January 2025. With virtually zero chance of a positive Phase 3 readout, YES shares are worthless. Buying NO at 0.61 offers an exceptional risk-adjusted return.

At 54%, the market underprices success. Phase 2 AN75 showed a ~29% delta over vehicle, providing a strong cushion for this well-powered Phase 3. Intrinsic odds are ~80%. Executing a max BUY_YES to capture the spread.

The market significantly underprices the likelihood of success given the robust Phase 1b PFS data (11.9 months) in this specific PD-L1 negative cohort, which strongly outperforms the historical control. Buying YES max.

The 85% intrinsic YES probability offers a massive premium over the 0.50 market price. Robust Phase 2 data and a sham-controlled Phase 3 design provide high confidence in clinical success, justifying a max BUY_YES.